Mirum Primary Endpoint Met in AZURE-4 Phase 3 in hep D

 Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a leading rare disease company, today announced that the primary endpoint was met in the Phase 3 AZURE-4 study evaluating brelovitug, an investigational fully human monoclonal antibody that binds to hepatitis B surface antigen (HBsAg), for the treatment of chronic hepatitis delta virus (HDV). AZURE-4 is the second of two Phase 3 studies that will form the basis of Mirum's U.S. registration package for brelovitug. 

https://www.businesswire.com/news/home/20261110113586/en/Mirum-Pharmaceuticals-Announces-Primary-Endpoint-Met-in-AZURE-4-Phase-3-Study-and-Highlights-Long-Term-Brelovitug-Data-Presented-at-AASLD